Original article Anaplastic transformation of low-grade gliomas (WHO II) on magnetic resonance imaging

Bobek-Billewicz, Barbara; Stasik-Pres, Gabriela; Hebda, Anna; Majchrzak, Krzysztof; Kaspera, Wojciech; Jurkowski, Marek K.

doi:10.5114/fn.2014.43784

Cited by 30 publications

(40 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our series, sensitivity and specificity remained high for these lesions using MRP. In addition, other series seem to endorse following changes in CBV for low-grade gliomas to detect anaplastic transformation as early as 1 year prior to the development of contrst-enhancement6,9,18). However, other modalities may be more efficacious in detecting progression earlier compared to MRP.…”

Section: Discussionmentioning

confidence: 99%

The Use of MR Perfusion Imaging in the Evaluation of Tumor Progression in Gliomas

Snelling

Shah

Buttrick

et al. 2017

J Korean Neurosurg Soc

View full text Add to dashboard Cite

ObjectiveDiagnosing tumor progression and pseudoprogression remains challenging for many clinicians. Accurate recognition of these findings remains paramount given necessity of prompt treatment. However, no consensus has been reached on the optimal technique to discriminate tumor progression. We sought to investigate the role of magnetic resonance perfusion (MRP) to evaluate tumor progression in glioma patients.MethodsAn institutional retrospective review of glioma patients undergoing MRP with concurrent clinical follow up visit was performed. MRP was evaluated in its ability to predict tumor progression, defined clinically or radiographically, at concurrent clinical visit and at follow up visit. The data was then analyzed based on glioma grade and subtype.ResustsA total of 337 scans and associated clinical visits were reviewed from 64 patients. Sensitivity, specificity, positive and negative predictive value were reported for each tumor subtype and grade. The sensitivity and specificity for high-grade glioma were 60.8% and 87.8% respectively, compared to low-grade glioma which were 85.7% and 89.0% respectively. The value of MRP to assess future tumor progression within 90 days was 46.9% (sensitivity) and 85.0% (specificity).ConclusionBased on our retrospective review, we concluded that adjunct imaging modalities such as MRP are necessary to help diagnose clinical disease progression. However, there is no clear role for stand-alone surveillance MRP imaging in glioma patients especially to predict future tumor progression. It is best used as an adjunctive measure in patients in whom progression is suspected either clinically or radiographically.

show abstract

Section: Discussionmentioning

confidence: 99%

The Use of MR Perfusion Imaging in the Evaluation of Tumor Progression in Gliomas

Snelling

Shah

Buttrick

et al. 2017

J Korean Neurosurg Soc

View full text Add to dashboard Cite

show abstract

“…Malignant transformation is functionally defined as occurring when a glioma increases in histological grade; however, this remains a poorly understood process by which gliomas somehow acquire more aggressive features ultimately leading to death from rapid and uncontrolled tumor growth. There is tremendous variability in the reported likelihood of malignant transformation, ranging anywhere from 35 to 89% of tumors evaluated [16–18]. The threat posed by malignant transformation is amplified by the fact that transformation usually occurs without apparent warning even in patients that may have been stable for many years.…”

Section: Discussionmentioning

confidence: 99%

Radial expansion rates and tumor growth kinetics predict malignant transformation in contrast-enhancing low-grade diffuse astrocytoma

et al. 2015

View full text Add to dashboard Cite

Summary Background Contrast-enhancing low-grade diffuse astrocytomas are an understudied, aggressive subtype at increased risk because of few radiographic indications of malignant transformation. In the current study, we tested whether tumor growth kinetics could identify tumors that undergo malignant transformation to higher grades. Methods Thirty patients with untreated diffuse astrocytomas (WHO II) that underwent tumor progression were enrolled. Contrast-enhancing and T2 hyperintense tumor regions were segmented and the radius of tumor at two time points leading to progression was estimated. Radial expansion rates were used to estimate proliferation and invasion rates using a biomathematical model. Results Radial expansion rates for both contrast-enhancing (p = 0.0040) and T2 hyperintense regions (p = 0.0016) were significantly higher in WHO II–IV tumors compared with nontransformers. Similarly, model estimates showed a significantly higher proliferation (p = 0.0324) and invasion rate (p = 0.0050) in WHO II–IV tumors compared with nontransformers. Conclusion Tumor growth kinetics can identify contrast-enhancing diffuse astrocytomas undergoing malignant transformation.

show abstract

“…The malignant transformation among low-grade gliomas with a WHO grade II ranges between 35 and 89 %. According to the reports of some authors, all gliomas of WHO grade II perform a malignant transformation over time [2,18]. The case of George Gershwin may be an example because his case report shows an indication of the existence of a low-grade glioma [5,9,11,12,16,17].…”

Section: Dear Editormentioning

confidence: 96%

Reply letter to the editor: the continuing story of George Gershwin and his brain tumor—would the outcome have been different today?

Gasenzer

Neugebauer

2015

Acta Neurochir

View full text Add to dashboard Cite

Original article Anaplastic transformation of low-grade gliomas (WHO II) on magnetic resonance imaging

Abstract: A b s t r a c t

Cited by 30 publications

References 40 publications

The Use of MR Perfusion Imaging in the Evaluation of Tumor Progression in Gliomas

The Use of MR Perfusion Imaging in the Evaluation of Tumor Progression in Gliomas

Radial expansion rates and tumor growth kinetics predict malignant transformation in contrast-enhancing low-grade diffuse astrocytoma

Reply letter to the editor: the continuing story of George Gershwin and his brain tumor—would the outcome have been different today?

Contact Info

Product

Resources

About